Glen Y. Sato
Corporate Officer/Principal bij Cooley LLP
Profiel
Glen Y.
Sato is currently a Partner at Cooley LLP since 2013 and a Member of The State Bar of California.
Previously, he was a Director at Intarcia Therapeutics, Inc., Lead Independent Director at Acucela, Inc. from 2013 to 2015, Chief Financial Officer & General Counsel at Exelixis, Inc. from 1999 to 2003, Chief Financial Officer & Senior Vice President at PDL BioPharma, Inc. in 2005, and Secretary at Anacor Pharmaceuticals LLC.
He is also a Member of the California State Bar Association.
Mr. Sato completed his graduate degree in 1987 and MBA in 1987 from the University of California, Los Angeles.
He also holds an undergraduate degree from Wesleyan University, which he completed in 1981.
Actieve functies van Glen Y. Sato
Bedrijven | Functie | Begin |
---|---|---|
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-01-2006 |
The State Bar of California
The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Corporate Officer/Principal | 18-11-2010 |
Eerdere bekende functies van Glen Y. Sato
Bedrijven | Functie | Einde |
---|---|---|
ACUCELA INC | Director/Board Member | 02-05-2015 |
California State Bar Association | Corporate Officer/Principal | 15-05-2014 |
PDL BIOPHARMA, INC. | Director of Finance/CFO | 01-09-2005 |
EXELIXIS, INC. | Director of Finance/CFO | - |
ANACOR PHARMACEUTICALS INC | Corporate Secretary | - |
Opleiding van Glen Y. Sato
University of California, Los Angeles | Graduate Degree |
Wesleyan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
EXELIXIS, INC. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Anacor Pharmaceuticals LLC
Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Commercial Services |
The State Bar of California
The State Bar of California Miscellaneous Commercial ServicesCommercial Services The State Bar of California operates as an official attorney licensing agency. The non-profit company is based in San Francisco, CA. Elizabeth Rindskopf Parker has been the CEO of the company since 2015. | Commercial Services |
California State Bar Association | |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |